Dyne Therapeutics Initiates Phase 3 FORZETTO Trial Of Zeleciment Rostudirsen In Individuals With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping

Benzinga Newsdesk www.benzinga.com Neutral 59.1%

Neg 0% Neu 59.1% Pos 0%

Comments

No comments yet. Be the first!